Compare WEC & RMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WEC | RMD |
|---|---|---|
| Founded | 1896 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Medical/Dental Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.8B | 33.6B |
| IPO Year | 1995 | 1996 |
| Metric | WEC | RMD |
|---|---|---|
| Price | $117.80 | $239.26 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 20 |
| Target Price | $118.50 | ★ $264.33 |
| AVG Volume (30 Days) | ★ 2.9M | 1.4M |
| Earning Date | 10-29-2026 | 10-29-2026 |
| Dividend Yield | ★ 3.24% | 1.10% |
| EPS Growth | N/A | ★ 9.67 |
| EPS | ★ 4.81 | 2.92 |
| Revenue | ★ $9,800,100,000.00 | $2,957,013,000.00 |
| Revenue This Year | $5.24 | $3.12 |
| Revenue Next Year | $6.03 | $6.43 |
| P/E Ratio | ★ $24.44 | $81.88 |
| Revenue Growth | ★ 13.96 | 13.44 |
| 52 Week Low | $99.80 | $180.27 |
| 52 Week High | $120.15 | $277.67 |
| Indicator | WEC | RMD |
|---|---|---|
| Relative Strength Index (RSI) | 67.69 | 52.90 |
| Support Level | $110.16 | $218.45 |
| Resistance Level | $118.91 | $257.89 |
| Average True Range (ATR) | 1.99 | 7.36 |
| MACD | 0.05 | -0.87 |
| Stochastic Oscillator | 75.23 | 56.48 |
WEC Energy Group's electric and gas utility businesses serve electric and gas customers in Illinois, Michigan, Minnesota, and Wisconsin service territories. The company also owns a 60% stake in American Transmission Co. WEC's asset mix is approximately 49% electric generation and distribution, 30% gas distribution, 10% electric transmission, 9% unregulated renewable energy, and 2% LNG distribution and generation.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea, combined with aging populations and increasing prevalence of obesity, is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.